Evodenoson

Drug Profile

Evodenoson

Alternative Names: ATL-313; DE-112

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Adenosine Therapeutics
  • Developer PGxHealth; Santen Pharmaceutical
  • Class Anti-inflammatories; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Haematological malignancies; Multiple sclerosis; Neuropathic pain; Ocular hypertension

Most Recent Events

  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 01 Feb 2012 Santen completes the phase I/II trial in Glaucoma in USA (NCT01279083)
  • 01 Feb 2012 Santen completes the phase I/II trial in Ocular hypertension in USA (NCT01279083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top